Arif Abdul Rehman, Zhou Hu, Fang Yongjun, Cheng Yunfeng, Ye Jieyu, Chen Wenlan, Ding Yajie, Cai Li, Xue Mei, Mei Heng, Wang Yadan
Department of Orthopaedic Trauma and Microsurgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei Province, China.
Department of Haematology, Henan Cancer Hospital/The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
J Thromb Haemost. 2025 Mar;23(3):1043-1051. doi: 10.1016/j.jtha.2024.12.001. Epub 2024 Dec 12.
Myosin heavy chain 9-related diseases (MYH9-RDs) are rare autosomal dominant platelet disorders characterized by macrothrombocytopenia and leukocyte inclusion bodies. They can manifest with nonhematological complications, including deafness, nephropathy, or cataracts. Due to its rarity and its similar clinical presentation with immune thrombocytopenia (ITP), MYH9-RD is often misdiagnosed as ITP, leading to inappropriate treatment and delayed management of complications.
This study aimed to evaluate clinical, therapeutic, and genetic aspects of patients with MYH9-RD misdiagnosed with ITP, comparing differences between Chinese pediatric and adult cases of this condition.
This multicenter retrospective study included data obtained from Chinese patients diagnosed with MYH9-RD between January 2014 and December 2023 at 5 centers.
Adults exhibited significantly longer median misdiagnosis (9 years vs 0.2 years, P < .001) and treatment durations (1.5 years vs 0.1 years, P < .001) than children. Nonhematological manifestations were exclusive to adults (10/21). All patients received inappropriate ITP treatments, with adults receiving more different treatments. Genetic analysis revealed 21 spontaneous mutations (52.5%), 12 familial mutations, and 7 mutations with unknown inheritance patterns. Two novel mutations (p.G1517V and p.K1674Q) were identified. Patients with the p.R702C mutation demonstrated early-stage kidney injury and hearing loss.
Adult patients with MYH9-RD have greater risk of misdiagnosis, prolonged inappropriate treatment, and nonhematological complications than pediatric patients. Enhanced awareness, consideration of mean platelet volume, family history, and genetic screening are crucial for accurate MYH9-RD diagnosis and management. The incidence of spontaneous mutations and identified genotype-phenotype correlations warrant further investigation in the Chinese population.
肌球蛋白重链9相关疾病(MYH9-RDs)是罕见的常染色体显性血小板疾病,其特征为大血小板减少和白细胞包涵体。它们可表现为非血液学并发症,包括耳聋、肾病或白内障。由于其罕见性以及与免疫性血小板减少症(ITP)相似的临床表现,MYH9-RD常被误诊为ITP,导致治疗不当和并发症管理延误。
本研究旨在评估被误诊为ITP的MYH9-RD患者的临床、治疗和遗传学方面,比较中国儿科和成人病例在这种情况下的差异。
这项多中心回顾性研究纳入了2014年1月至2023年12月期间在5个中心诊断为MYH9-RD的中国患者的数据。
成人的中位误诊时间(9年 vs 0.2年,P <.001)和治疗持续时间(1.5年 vs 0.1年,P <.001)明显长于儿童。非血液学表现仅见于成人(10/21)。所有患者均接受了不适当的ITP治疗,成人接受的不同治疗更多。基因分析发现21个自发突变(52.5%)、12个家族性突变和7个遗传模式不明的突变。鉴定出两个新突变(p.G1517V和p.K1674Q)。携带p.R702C突变的患者表现出早期肾损伤和听力丧失。
与儿科患者相比,成人MYH9-RD患者误诊风险更高、不适当治疗时间更长且有非血液学并发症。提高认识、考虑平均血小板体积、家族史和基因筛查对于准确诊断和管理MYH9-RD至关重要。自发突变的发生率以及已确定的基因型-表型相关性值得在中国人群中进一步研究。